

## Forbes Calculates Average Drug Development Cost at \$4-\$11 Billion

By Donald Zuhn -- February 15, 2012

Last week, Forbes reported that the development costs for an average drug (produced by a major pharmaceutical company) are at least \$4 billion, and as much as \$11 billion ("The Truly Staggering Cost Of billion, and as much as \$11 billion ("The Truly Staggering Cost Of Inventing New Drugs"). The article, by Forbes science and medicine

writer Matthew Herper, notes that the drug industry pegs average drug development costs at \$1 billion, and that Bernard Munos of the InnoThink Center for Research In Biomedical Innovation, adjusting for current failure rates, arrives at an estimate of \$4 billion. Seeking a more rigorous estimate, Mr. Herper and Forbes writer Scott DeCarlo combined Mr. Munos' drug approval counts with the research and development spending for a dozen major pharmaceutical companies, as reported in annual earnings filings over the past fifteen years (pulled from a Thomson Reuters database using FactSet), and adjusted the resulting figures for inflation. Their calculations showed that of the twelve pharma companies, AstraZeneca spent the most R&D money per approved drug (nearly \$11.8 billion) and Amgen spent the least (almost \$3.7 billion). The other companies on Forbes' list were Novartis, Bristol-Myers Squibb, Merck, Abbott Laboratories, Eli Lilly, Johnson & Johnson, Pfizer, Roche, Sanofi, and GlaxoSmithKline. The number of drug approvals, R&D spending per drug approval, and total R&D spending for each of the above companies can be found in the Forbes article.

"Patent Docs" does not contain any legal advice whatsoever. This weblog is for informational purposes only, and its publication does not create an attorneyclient relationship. In addition, nothing on "Patent Docs" constitutes a solicitation for business. This weblog is intended primarily for other attorneys. Moreover, "Patent Docs" is the personal weblog of the Authors; it is not edited by the Authors' employers or clients and, as such, no part of this weblog may be so attributed. All posts on "Patent Docs" should be double-checked for their accuracy and current applicability.